发布时间：2025-10-30 10:23



SAINT-PREX, Switzerland--(BUSINESS WIRE)--As part of our ongoing transformation to sharpen our focus, we have decided to explore strategic options for Rebyota®(faecal microbiota, live – jslm). To date, more than five thousand patients suffering from recurrentClostridioides difficileinfection (rCDI) have found new hope when treated with Rebyota®. Without commercial critical mass in this therapy area at Ferring, we believe that this first-in-class, innovative product could benefit many more patients with a new approach to its continued commercialisation. As a result, Ferring will reduce commercial efforts in the United States while ensuring uninterrupted access for patients.

Approved by the U.S. Food and Drug Administration (FDA) in 2022, Rebyota®was the first FDA-approved faecal microbiota transplant, indicated for the prevention of rCDI in adults following antibiotic treatment for recurrent CDI. This milestone
=*=*=*=*=*=
当前为第1/5页
下一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页